Hutchinson-Gilford progeria syndrome (HGPS) is caused by the production of a truncated prelamin A, called progerin, which is farnesylated at its carboxyl terminus. Progerin is targeted to the nuclear envelope and causes misshapen nuclei. Protein farnesyltransferase inhibitors (FTI) mislocalize progerin away from the nuclear envelope and reduce the frequency of misshapen nuclei. To determine whether an FTI would ameliorate disease phenotypes in vivo, we created gene-targeted mice with an HGPS mutation (Lmna HG/+ ) and then examined the effect of an FTI on disease phenotypes. Lmna HG/+ mice exhibited phenotypes similar to those in human HGPS patients, including retarded growth, reduced amounts of adipose tissue, micrognathia, osteoporosis, and osteolytic lesions in bone. Osteolytic lesions in the ribs led to spontaneous bone fractures. Treatment with an FTI increased adipose tissue mass, improved body weight curves, reduced the number of rib fractures, and improved bone mineralization and bone cortical thickness. These studies suggest that FTIs could be useful for treating humans with HGPS.
Introduction
Hutchinson-Gilford progeria syndrome (HGPS) is a rare pediatric progeroid syndrome characterized by multiple disease phenotypes, including slow growth, sclerodermatous changes of the skin, alopecia, micrognathia, osteoporosis, osteolytic lesions in bone, and occlusive atherosclerotic vascular disease (1) (2) (3) (4) (5) . HGPS is caused by an LMNA mutation that results in the synthesis of a mutant prelamin A, commonly called progerin, that contains a 50-amino-acid deletion within the carboxyterminal portion of the protein (2, 6) . Progerin undergoes farnesylation at a carboxyterminal CaaX motif, but it lacks the cleavage site for the endoprotease ZMPSTE24 and therefore cannot be further processed to mature lamin A (2, 6) . Within cells, progerin is targeted to the nuclear envelope, where it interferes with the integrity of the nuclear lamina and causes misshapen nuclei (7) (8) (9) .
We suspected that protein farnesylation might be crucial for the targeting of progerin to the nuclear rim, and we hypothesized that blocking farnesylation with a farnesyltransferase inhibitor (FTI) would mislocalize progerin away from the nuclear rim and reduce the frequency of misshapen nuclei (6, 9, 10) . Indeed, this was the case; an FTI reduced the number of misshapen nuclei in fibroblasts from mice with a targeted HGPS mutation (9) . Subsequently, we (10) and others (11) (12) (13) showed that FTIs also improved nuclear shape in fibroblasts from humans with HGPS.
The fact that FTIs improved nuclear shape in HGPS cells raised hope for a potential therapy and stimulated interest in testing the efficacy of FTIs in a gene-targeted mouse model of HGPS (6, (9) (10) (11) (12) (13) . In this study, we describe disease phenotypes in mice carrying a targeted HGPS mutation and define the impact of FTI treatment on the course of the disease. HG/+ mice. The tissues of Lmna HG/+ mice (mice heterozygous for a targeted HGPS mutation [ref. 9] yielding exclusively progerin) expressed lamin A, lamin C, and progerin. The amount of progerin in both liver and aorta was greater than that of lamin A or lamin C, as judged by Western blotting ( Figure 1A ). Homozygous mice (Lmna HG/HG ) expressed exclusively progerin ( Figure 1A) .
Results

Slow growth, bone abnormalities, and loss of fat in Lmna
Lmna HG/+ mice appeared normal for the first 3 weeks of life. By 6-8 weeks, however, both male and female Lmna HG/+ mice began to lose weight ( Figure 1B ). The survival of Lmna HG/+ mice was reduced ( Figure 1C) . Also, Lmna HG/+ mice had significantly less subcutaneous fat and abdominal fat (Figure 1 , D and E) and exhibited more kyphosis of the spine (Figure 2, A and B) . Lmna HG/+ mice invariably developed osteolytic lesions in the ribs, predisposing to rib fractures near the costovertebral junction ( Figure 2 , C and D). By 18 weeks of age, all Lmna HG/+ mice (n = 11 examined) developed osteolytic lesions in the posterior portion of the zygomatic arch (Figures 2, E and F); they also had micrognathia and a reduction in the zigzag appearance of the cranial sutures ( Figure 2 , E and F). Some Lmna HG/+ mice had osteolytic lesions in other sites (e.g., clavicle, scapula, calvarium, and mandible). The Lmna HG/+ mice became progressively malnourished, and 50% (39/78) died or were so sick that they had to be euthanized by 27 weeks of age.
Many of the phenotypes in Lmna HG/+ mice (e.g., slow growth, weight loss, loss of adipose tissue, kyphosis, osteolytic lesions in the zygomatic arch, and fractured ribs at the costovertebral junction) are shared by Zmpste24 -/-mice (14, 15) . However, one difference was noteworthy: Zmpste24 -/-mice developed a grip strength abnormality (inability to hang upside down from a grid at 4 months of age) (14, 15) , whereas in Lmna HG/+ mice the grip strength was invariably normal ( Figure 2G ). No histological abnormalities in skeletal muscle were identified in Lmna HG/+ mice. The aortas of 6- to 7-month-old mice (n = 8) were also examined by routine histology; the intima, media, and adventitia of Lmna HG/+ aortas were normal, free of lesions, and indistinguishable from those of Lmna +/+ (wild-type) mice ( Figure 2H) .
Early death and severe bone abnormalities in Lmna HG/HG mice. In sustained breeding efforts, we were able to obtain only a few (n = 12) homozygous mice (Lmna HG/HG ). Lmna HG/HG mice were invariably very small (approximately one-half the size of their littermates), with a complete absence of adipose tissue, and many had spontaneous bone fractures in the extremities (Figure 3, A and B) . All Lmna HG/HG mice died by 3-4 weeks of age ( Figure 1C) . As judged by μCT scans, the bones of Lmna HG/HG mice were poorly mineralized; the mice also had micrognathia and an abnormal skull shape, with open cranial sutures ( Figure 3, C-F (17) , in the drinking water (39 mg/kg body weight) to groups of 7-10 male and female Lmna HG/+ mice and 6-9 male and female littermate Lmna +/+ mice, beginning at 4 weeks of age. Biomarker studies indicated that the FTI was active in vivo. First, the FTI interfered with the biogenesis of mature lamin A from the wild-type (Lmna + ) allele, resulting in the appearance of nonfarnesylated prelamin A in the livers of FTI-treated mice, which could be readily detected by Western blotting with a prelamin A-specific antibody ( Figure 5A ). Second, Western blots of HDJ-2, a chaperone protein that is normally farnesylated, revealed that approximately 70-80% of the HDJ-2 in the livers of FTI-treated mice was nonfarnesylated ( Figure 5A ).
In Lmna +/+ female mice, the FTI reduced body weight compared with Lmna +/+ mice given the vehicle alone (P = 0.03) ( Figure 5B) ; however, the FTI had no apparent effect on weight gain in male Lmna +/+ mice ( Figure 5C ). Aside from the minor changes in body weight in the female mice, the FTI had no noticeable side effects. In contrast, the FTI improved body weight curves in both female and male Lmna HG/+ mice (P < 0.0001) ( Figure 5 , B and C). FTI treatment increased the weight of the major fat pads in Lmna HG/+ mice (P = 0.002) ( Figure 5D ) and also increased the amount of fat in subcutaneous tissues ( Figure 5E ).
The FTI treatment significantly improved, but did not completely cure, the bone disease in Lmna HG/+ mice. The degree of kyphosis was reduced in FTI-treated Lmna HG/+ mice (kyphotic index: 3.32 ± 0.37 in FTI-treated Lmna HG/+ mice versus 1.91 ± 0.38 in vehicle-treated littermate Lmna HG/+ mice; P = 0.02) ( Figure 6 , A and B). The FTItreated mice also developed fewer rib fractures (1.13 ± 1.45 in FTItreated Lmna HG/+ mice versus 9.1 ± 3.76 in vehicle-treated littermate Lmna HG/+ mice; P < 0.0001) ( Figure 6C ). The reduced number of rib fractures was evident on μCT scans ( Figure 6D ). FTI treatment of Lmna HG/+ mice also led to an improvement in bone mineralization and cortical thickness ( Figure 6 , E and F).
Discussion
Our first goal was to define the phenotype of gene-targeted mice expressing progerin, the mutant protein responsible for HGPS. The Lmna HG/+ mice were normal at birth but then exhibited many of the hallmarks that appear early on in humans with HGPS, such as slow growth, osteolytic lesions in bone, osteoporosis, micrognathia, and loss of adipose tissue. These phenotypes were even more dramatic in Lmna HG/HG mice. A second goal was to determine whether treatment with an FTI would ameliorate disease phenotypes in Lmna HG/+ mice. Our studies provided a clear answer: an FTI, administered at 4 weeks of age, improved body weight curves, prevented loss of adipose tissue, improved bone mineralization, and reduced the number of rib fractures. Very recently, Fong et al. (18) reported that an FTI ameliorated disease phenotypes in Zmpste24 -/-mice. An absence of ZMPSTE24, the prelamin A endoprotease, leads to an accumulation of wild-type prelamin A - not the progerin molecule found in humans with HGPS. The current studies with a mouse HGPS model showed that an FTI ameliorates disease phenotypes caused by progerin, providing support for the notion that FTIs could be useful for treating human HGPS patients.
The phenotypes in Lmna HG/+ mice closely resemble those in Zmpste24 -/-mice. These phenotypic similarities were reassuring, given that both mouse models have an accumulation of one form of farnesyl-prelamin A (a wild-type prelamin A in Zmpste24 deficiency and the truncated prelamin A in HGPS). However, one phenotypic difference was clear: unlike the Zmpste24 -/-mice, Lmna HG/+ mice did not develop a grip strength abnormality. The absence of the grip abnormality in Lmna HG/+ mice underscores that these mice constitute a faithful model of human HGPS, since children with HGPS do not exhibit significant muscle weakness (1). It is not clear why the Zmpste24 -/-mice had muscle weakness, whereas the Lmna HG/+ mice did not. Clearly, the Zmpste24 -/-mice are sicker mice, in general, than the Lmna HG/+ mice, but that may not be the entire explanation, since Lmna HG/+ mice retained normal grip strength even when they were very debilitated. The expression of severe disease phenotypes in mice heterozygous for the Lmna HG allele underscores the potency of progerin in eliciting disease phenotypes. Other groups had previously used gene targeting to create mice with a Lmna-knockout mutation (16) and various Lmna missense mutations (19) (20) (21) . In those cases, homozygous mice had distinct phenotypes, whereas the heterozygous mice were indistinguishable from wild-type mice.
Occlusive disease of the large arteries is a late phenotype of humans with HGPS, apparent during the second decade of life and often leading to fatal stroke or myocardial infarction. The mechanisms underlying the occlusive arterial disease are uncertain. Pathologic studies of several progeria patients by Stehbens and coworkers (4, 5) and Ackerman and Gilbert-Barness (3) revealed moderately severe atherosclerotic lesions in the arterial intima along with the loss of some smooth muscle cells in the arterial media. The Lmna HG/+ mice did not have histopathological abnormalities in the intima or media of the aorta, even though they clearly exhibited many of the early hallmarks of HGPS. We do not know why the Lmna HG/+ mice did not develop disease in their large arteries, but we suspect that they simply did not live long enough for this late HGPS phenotype to emerge. Recently, Varga et al. (22) created transgenic mice with a 164-kb human bacterial artificial chromosome spanning 4 genes - RAB25, UBQLN4, MAPBPIP, and LMNA (engineered to contain the G608G HGPS mutation; ref.
2). The amount of progerin expressed in the tissues of transgenic mice, relative to the amounts of human and mouse lamin A and lamin C, was not clear. The transgenic mice did not manifest any of the early hallmarks of progeria, nor did they have arterial intimal lesions or vascular occlusions, but they did exhibit loss of smooth muscle cells in the media of the aorta (22) . The explanation for this constellation of findings is not clear.
In this study, an FTI ameliorated disease phenotypes in Lmna HG/+ mice but fell short of curing the disease. The concentration of the FTI in the plasma of mice in these studies was low relative to that achieved in earlier anticancer studies (17) ; in the future, it will be interesting to determine whether a higher dose of an FTI would be more efficacious in preventing disease. Also, it will be important to test the efficacy of an FTI in reversing disease phenotypes in mice after they are well established, as the ability to reverse disease will be of paramount importance to HGPS patients who already suffer from advanced 
Figure 4
More severe nuclear blebbing in Lmna HG/HG embryonic fibroblasts than in Lmna HG/+ and Lmna +/+ fibroblasts. The frequency of nuclear blebs in Lmna HG/HG embryonic fibroblasts, compared with Lmna HG/+ and Lmna +/+ fibroblasts, was significantly increased (P < 0.0001 for both comparisons). Treatment of cells with an FTI (2.5 μM ABT-100) reduced the frequency of misshapen nuclei (P < 0.0001). Black circles in each bar indicate the results obtained with 2 independent cell lines; ratios within each bar represent the number of cells with misshapen nuclei over the total number of cells evaluated.
disease. Another key issue for future studies will be to determine whether nonfarnesylated progerin (which is present during FTI treatment) has the potential to elicit disease phenotypes over the long term.
Methods
A gene-targeted model of HGPS. Previously, we generated chimeric mice from mouse embryonic stem cells with a mutant Lmna allele (Lmna HG ) yielding exclusively progerin and bred those mice to generate Lmna HG/+ embryonic fibroblasts (9) . In the current study, we bred Lmna HG/+ mice to obtain Lmna HG/HG mice. Genotyping was performed by PCR with genomic DNA from tail biopsies (9) . All mice had a mixed genetic background (~75% C57BL/6 and ~25% 129/OlaHsd). The mice were fed a chow diet and housed in a virus-free barrier facility with a 12-hour light/12-hour dark cycle. Body weights and the ability to hang upside down from a grid (14) were assessed weekly. UCLA's Animal Research Committee approved all procedures.
An FTI, ABT-100 (17), was mixed in drinking water containing 0.4% hydroxy propyl methyl cellulose and 1.0% ethanol at a concentration of 0.3 mg/ml, so as to deliver a dose of approximately 39 mg/kg/d. The vehicle control consisted of drinking water with 0.4% hydroxy propyl methyl cellulose and 1.0% ethanol. Blood samples were collected between 4:00 and 5:30 am; the mean concentration of ABT-100 in the plasma of Lmna HG/+ mice (n = 5) was 0.7104 μg/ml. The treatments were continued until 6 months of age; at that point, surviving mice were euthanized.
Tomographic analyses. Lmna +/+ , Lmna HG/+ , and Lmna HG/HG mice were examined by compact cone-beam tomography (μCT 40 scanner; Scanco Medical). Whole-body scans were performed in the axial plane mounted in a cylindrical sample holder at medium resolution with a current of 0.16 mA and a voltage of 70 kilovolt peak (kVp), at an isotropic voxel size of 20.5 μm for the skulls and 30.7 μm for the remainder of the skeleton.
Cortical thickness and degree of mineralization of the cortical bone in the proximal portion of the posterior ninth left rib were determined by μCT scanning; the X-ray tube operated at 55 kVp and 145 μA. Scans of transverse sections of the rib were obtained at 10-μm nominal resolution (high-resolution mode). Two-dimensional images were reconstructed in 2,048 × 2,048-pixel matrices using a standard convolution back-projection procedure with a Shepp and Logan filter, and a cortical volume of interest (VOI) was defined for each measurement. A constrained 3-dimensional Gaussian filter was used to suppress noise. The mineralized tissue was segmented with a fixed threshold for all samples. A manufacturerprovided hydroxyapatite phantom of known density was used to calibrate the system, allowing us to estimate the degree of mineralization of the cortical bone tissue.
Standard skeletal X-rays were performed with a Faxitron X-ray system (Faxitron X-ray Corp.) at 30 kV for 2 seconds. The degree of kyphosis of the spine (kyphotic index) was calculated as described previously (23) .
Analysis of rib fractures in Lmna HG/+ mice. Lmna +/+ and Lmna HG/+ mice were euthanized at 8, 16, 24, and 28 weeks of age. The interior of the thorax was photographed with a digital camera, and rib fractures were counted. 
